|
Daily Medical Update
Postherpetic Neuralgia
Friday, June 26, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Frontiers in immunology (2025) - Meta-Analysis
Key Findings
- Age 60 years or older, severe rash, prodromal pain, immunosuppressive therapy, and smoking were all associated with increased PHN risk across pooled analyses.
- Alcohol abuse, diabetes, COPD, hypertension, cancer, higher acute VAS/NRS pain scores, and higher herpes zoster viral load were also associated with increased PHN risk, while VZV antibody levels appeared protective.
📋 Practice Implication: Use acute zoster visits to identify patients with multiple PHN risk factors and justify earlier antivirals, closer follow-up, and more aggressive early pain control.
|
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP (2025) - RCT
Key Findings
- At 8 weeks, gabapentin plus low-dose pregabalin reduced VAS pain scores more than gabapentin alone.
- Clinical efficacy was higher with combination therapy than monotherapy (74.6% vs 56.7%, p = 0.029), with lower IL-6, IL-1beta, and TNF-alpha and no significant increase in adverse effects.
📋 Practice Implication: For patients still uncontrolled on gabapentin, a cautious gabapentin-pregabalin combination may be a reasonable short-term escalation before moving to procedural therapy.
|
Neuromodulation : journal of the International Neuromodulation Society (2025) - Meta-Analysis
Key Findings
- Temporary spinal cord stimulation reduced pain more than pulsed radiofrequency at 1 month (MD -0.98), 3 months (MD -1.34), and 6 months (MD -1.27).
- Treatment success over 50% pain reduction favored spinal cord stimulation at 3 months and later, with lower pregabalin use and better quality-of-life scores from 6 months onward.
📋 Practice Implication: When medication-refractory PHN is being considered for intervention, temporary spinal cord stimulation has stronger mid-term outcome data than pulsed radiofrequency.
|
Clinical neuropharmacology (2025) - RCT
Key Findings
- Botulinum toxin type A added to standard care reduced VAS pain scores and inflammatory markers more than standard care alone.
- IL-6 predicted improved treatment response with an AUC of 0.804, and adverse events were rare and similar between groups.
📋 Practice Implication: Botulinum toxin A is a plausible office-based adjunct for refractory PHN, especially when clinicians want a non-systemic option with limited short-term toxicity.
|
British journal of anaesthesia (2025) - Meta-Analysis
Key Findings
- Across 69 studies, improved adherence to neuropathic pain medications was associated with serotonin-norepinephrine reuptake inhibitors, dose titration, and use of medication reminders.
- Increased discontinuation was associated with tricyclic antidepressants and combination pharmacotherapy, while recommended prescribing was less likely in ethnic minorities and people without diabetes.
📋 Practice Implication: Build PHN follow-up around titration plans, reminder supports, and regimen simplification because persistence may fail even when initial prescribing is guideline-concordant.
|
|
💡
Summary
Recent postherpetic neuralgia evidence emphasizes earlier risk stratification and more selective escalation for refractory pain, with newer studies showing benefit from combination gabapentinoids, botulinum toxin A, and temporary spinal cord stimulation in appropriate patients. Broader neuropathic pain adherence data also suggest that titration, reminders, and avoiding unnecessary combination therapy may improve persistence once a PHN regimen is started.
|
|